Premium
lncRNA FBXL19‐AS1 is a diagnosis biomarker for paediatric patients with acute myeloid leukemia
Author(s) -
Sheng Hongling,
Zhang Jiajia,
Ma Yan,
Zhang Yuhua,
Dai Yunpeng,
Jiang Renpeng
Publication year - 2021
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.3317
Subject(s) - myeloid leukemia , biomarker , medicine , myeloid , oncology , intensive care medicine , biology , genetics
Background Long non‐coding RNAs (lncRNA) have emerged as novel clinical biomarkers and therapeutic targets for various tumors because of their disease‐ and stage‐restricted expression. lncRNA FBXL19 antisense RNA 1 (FBXL19‐AS1) expression has been confirmed to be up‐regulated in several tumors. However, its expression and effects in paediatric acute myeloid leukemia (AML) have not been elucidated. Methods Serum FBXL19‐AS1 expression was determined in 137 AML patients compared to 43 healthy controls ( < 0.01). Results Using receiver operating characteristic curve analysis, we observed that serum FBXL19‐AS1 provided the highly diagnostic performance for the detection of AML (AUC = 0.841, < 0.001). We also examined the association between serum FBXL19‐AS1 expression and clinicopathological factors, finding that its high expression was associated with French–American–British classification ( = 0.011) and cytogenetics ( = 0.021). Survival assays with the Kaplan–Meier method revealed that the overall survival ( = 0.0088) and disease‐free‐survival ( = 0.0027) of AML patients with high serum FBXL19‐AS1 levels were distinctly shorter compared to those with low serum FBXL19‐AS1 levels. More importantly, Multivariate analysis identified serum FBXL19‐AS1 overexpression as an independent unfavorable prognostic factor for both overall survival and disease‐free‐survival of AML patients. Conclusions Overall, our findings revealed that high expression of serum FBXL19‐AS1 might be useful as a novel prognostic and diagnostic biomarker for AML patients.